Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ Origin: Appendix 5 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13$

Name of entity	Sundance Resources Limited		
	Name of entity		

ABN

19 055 719 394

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to be issued **Fully Paid Ordinary Shares**

Number of *securities issued or to be issued (if known) or maximum number which may be issued

111,428,571 fully paid ordinary shares

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Fully Paid Ordinary Shares on conversion of Convertible Notes.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

The shares will rank equally in all respects with existing fully paid ordinary shares.

5 Issue price or consideration

\$0. 0035 per share.

Appendix 3B Page 1 04/03/2013

⁺ See chapter 19 for defined terms.

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Conversion of 3,900 2016 Investor Group Notes
6a	Is the entity an +eligible entity	Yes
9u	that has obtained security holder approval under rule 7.1A?	
	If Yes, complete sections 6b – 6h <i>in</i> relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder	17 Fohruary 2017
OD	resolution under rule 7.1A was passed	17 February 2017
6-	N. 1. C. 1 1.	Alt
6с	Number of *securities issued without security holder approval under rule 7.1	Nil
. 1		F
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6-	N. 1. C. 1 1.	21/2
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
	(1)	
6f	Number of *securities issued under an exception in rule 7.2	111,428,571 fully paid ordinary shares issued on 26 February 2018 upon conversation of 3,900 \$100 2016 Investor Group Convertible Notes held by Senrigan Master Fund
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Nil
6h	If +securities were issued under	Nil
-	rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market	

Announcements

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7.1 capacity - **1,210,627,028** 7.1A capacity - **807,084,685**

7	+Issue	dates
/	ISSUE	uates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

26 February 2018	

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class	
8,070,846,852	Fully paid ordinary shares	

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

Number	⁺ Class
	UNLISTED OPTIONS
260,000,000	Investor Consortium Options
	exercisable at \$0.0695 per
	option
200,000,000	Noble Options exercisable at
	\$0.0695 per option
260,000,000	Wafin Options exercisable at
	\$0.0695 per option
100,000,000	2017 Options exercisable at \$0.003
	per option vesting 1/12/2017
100 000 000	expiring 7/4/2022
100,000,000	2017 Options exercisable at \$0.006 per option vesting 1/12/2018
	expiring 7/4/2023
920,000,000	expiring 7/4/2023
320,000,000	
	PERFORMANCE RIGHTS
<u>3,956,839</u>	2014 LTI
3,956,839	
200.000	CONVERTIBLE NOTES
200,000	Noble
240,000	Investor Consortium
400,000	Wafin
70,000	2015 Investor Group
2,600 912,600	2016 Investor Group
312,000	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Appendix 3B Page 3 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2 - Pro rata issue

11	Is security holder approval N/A required?
	•
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the ⁺ securities will N/A be offered
14	⁺ Class of ⁺ securities to which the offer relates
15	⁺ Record date to determine N/A entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of N/A acceptances or renunciations
20	Names of any underwriters N/A
21	Amount of any underwriting fee N/A or commission
22	Names of any brokers to the issue N/A
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A
	B - Quotation of securities I only complete this section if you are app	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	1
(b)		nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible

Appendix 3B Page 5 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

	indicate you are providing the information	
35		securities, the names of the 20 largest holders of the number and percentage of additional *securities
36		securities, a distribution schedule of the additiona mber of holders in the categories
37	A copy of any trust deed for t	he additional ⁺ securities
Entitie	s that have ticked box 34(b)	
38	Number of *securities for which *quotation is sought	
39	⁺ Class of ⁺ securities for which quotation is sought	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend,	
	distribution or interest payment	
41	Reason for request for quotation now Example: In the case of restricted securities, end	
	of restriction period (if issued upon conversion of another *security, clearly identify that other *security)	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Number	+Class

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

...... Date: 26 February 2018

(Director/Company Secretary)

Print name: CAROL MARINKOVICH

== == == ==

Appendix 3B Page 7 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	7,000,658,916	
 Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	100,000,000 (issue to Exec Mgmt under new salary structuring arrangements) 21 February 2017 1,318,121 (options exercised under the Entitlement Offer dated 3 February 2016) 14 March 2017 46,580 (options exercised under the Entitlement Offer dated 3 February 2016) 20 June 2017 384,133 (options exercised under the Entitlement Offer dated 3 February 2016) 11 August 2017 3,174,715 (options exercised under the Entitlement Offer dated 3 February 2016) 25 August 2017 42,610,469 (options exercised under the Entitlement Offer dated 3 February 2016) 7 September 2017 5,400 (options exercised under the Entitlement Offer dated 3 February 2016) 7 September 2017 386,044,838 (Issued under Share Purchase Plan announced 25 August 2017) 25 September 2017	

⁺ See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013

"A"	8,070,846,852
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil
	111,428,571 (issue to Senrigan) 26 February 2018
	185,714,286 (issue to Noble) 13 February 2018
	147,345,679 (issue to Hanlong) 4 December 2017
	92,115,144 (Top-up Placement to sophisticated investors announced 25 August 2017) 25 September 2017 Approved by Shareholders 29 November 2017

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	1,210,627,028

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period *not counting* those issued:

- Under an exception in rule 7.2
- Under rule 7.1A
- With security holder approval under rule 7.1 or rule 7.4

Note:

- This applies to equity securities, unless specifically excluded – not just ordinary securities
- Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed
- It may be useful to set out issues of securities on different dates as separate line items

"C" Nil

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15	1,210,627,028

⁺ See chapter 19 for defined terms.

o4/o3/2013 Appendix 3B Page 9

Note: number must be same as shown in Step 2	
Subtract "C"	Nil
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	1,210,627,028

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	807,084,685	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	807,084,685
Subtract "E" Note: number must be same as shown in Step 3	Nil
Total ["A" x 0.10] – "E"	807,084,685

⁺ See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013